Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours

• Unité de recherche: INNOSUISSE
• Numéro de projet: 15808.1 PFLS-LS
• Titre du projet anglais: Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours

Description succincte (Allemand)

Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours

Description succincte (Anglais)

Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours

Résumé des résultats (Abstract) (Allemand)

The aim of this project is to complete key early developmental experiments for an anti-tumour peptide analogue therapy for patients with rare neuroendocrine tumours or acromegaly resistant, or poorly controlled, with available somatostatin analogues. The peptide analogue has high affinity for the two most important somatostatin receptors in growth hormone control, SSTR2 and 5. This novel tandem therapy will provide enhanced life expectancy, better clinical control and improved quality-of-life to the population of uncontrolled patients.

Résumé des résultats (Abstract) (Anglais)

The aim of this project is to complete key early developmental experiments for an anti-tumour peptide analogue therapy for patients with rare neuroendocrine tumours or acromegaly resistant, or poorly controlled, with available somatostatin analogues. The peptide analogue has high affinity for the two most important somatostatin receptors in growth hormone control, SSTR2 and 5. This novel tandem therapy will provide enhanced life expectancy, better clinical control and improved quality-of-life to the population of uncontrolled patients.